US warns of drugs in Reumofan dietary supplements

(AP) — The U.S. Food and Drug Administration is warning consumers not to use Reumofan dietary supplements, after receiving reports of bleeding, stroke and death among Americans taking the Mexico-manufactured pills.

Reumofan Plus and Reumofan Plus Premium are marketed as natural remedies for arthritis and muscle pain, but the FDA says the actually contain several prescription drugs.

A chemical analysis by the agency found that Reumofan Plus contains three drugs, including the muscle relaxant methocarbomal and the anti-inflammatory dexamethasone. These drugs can interact with other medications, causing life-threatening side effects in some patients.

The FDA first warned consumers about the products in June, but says complications have continued to be reported.

Reumofan products are manufactured in Mexico by Riger Naturals and sold in the U.S. at retail shops and over the Internet.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA seizes sexual enhancement products

Apr 10, 2008

The U.S. Food and Drug Administration announced the seizure by U.S. marshals of more than 14,000 units of Shangai- and Naturale-brand diet supplements.

FDA cracks down on illegal supplements

Dec 15, 2010

(AP) -- The Food and Drug Administration is cracking down on manufacturers of certain weight loss, body building and sexual enhancement supplements that contain potentially dangerous ingredients.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments